RNA Leaders Europe Congress

Add to calender
Research

Oral presentation title: Unlocking the potential of Axiomer® platform to develop transformative RNA editing therapies

Presenter: Daniel A. de Boer, Founder and CEO, ProQR Therapeutics

Date: Thursday, March 16 – 14:35 CET

Abstract: The presentation will describe: Axiomer, the next-generation RNA technology using the cell’s own editing machinery; explore therapeutic opportunities of Axiomer, beyond disease-causing mutations; and the advancement of Axiomer through in-house pipeline programs and partnering strategy.

You might like this

  • Press releases

    Read the latest news on our development programs, business updates and announcements. You can sign up for email alerts so you stay up to date on all things ProQR.

    Female scientist working in ProQR's laboratories

  • Our science

    Our passion lies in discovering the latest RNA technologies and translating them to life-changing treatments for people with genetic diseases.

    Axiomer RNA editing platform technology

  • About ProQR Therapeutics

    ProQR was founded by Daniel de Boer with a mission to help people living with rare genetic diseases. This remains the sole focus of our company today.

    Daniel de Boer wearing a blue suit stands with arm crossed in a laboratory setting.